Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) and Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Profitability
This table compares Palvella Therapeutics and Allogene Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Palvella Therapeutics | N/A | -47.84% | -38.33% |
| Allogene Therapeutics | N/A | -50.04% | -36.74% |
Valuation & Earnings
This table compares Palvella Therapeutics and Allogene Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Palvella Therapeutics | $42.81 million | 52.93 | -$41.72 million | ($4.83) | -32.55 |
| Allogene Therapeutics | $20,000.00 | 34,030.76 | -$190.89 million | ($0.67) | -2.94 |
Palvella Therapeutics has higher revenue and earnings than Allogene Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Palvella Therapeutics and Allogene Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Palvella Therapeutics | 1 | 0 | 12 | 2 | 3.00 |
| Allogene Therapeutics | 1 | 3 | 8 | 1 | 2.69 |
Palvella Therapeutics currently has a consensus price target of $209.14, indicating a potential upside of 33.01%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 321.32%. Given Allogene Therapeutics’ higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Palvella Therapeutics.
Volatility and Risk
Palvella Therapeutics has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
About Palvella Therapeutics
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
About Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
